The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Expands bioprocessing footprint across Asia
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Subscribe To Our Newsletter & Stay Updated
